Immunologic therapy targeting metastatic melanoma: Allovectin-7®

Immunotherapy

Volumn 3, Issue 1, 2011, Pages 17-21

  Chowdhery, Rozina ^a   Gonzalez, Rene ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

2 microglobulin; Allovectin 7 ; gene therapy; HLA B7; melanoma; MHC; plasmid DNA lipid complex

Indexed keywords

DACARBAZINE; TEMOZOLOMIDE; VELIMOGENE ALIPLASMID;

ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ECCHYMOSIS; HUMAN; INJECTION SITE PAIN; MELANOMA; METASTASIS; PAIN; PNEUMOTHORAX; PRIORITY JOURNAL; PRURITUS; TREATMENT RESPONSE; TUMOR BIOPSY;

CLINICAL TRIALS AS TOPIC; DNA, RECOMBINANT; GENE THERAPY; HLA-B7 ANTIGEN; HUMANS; IMMUNOTHERAPY; LIPIDS; LIPOSOMES; MELANOMA; NEOPLASM METASTASIS; PLASMIDS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 78650555335     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.89     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics 2010, Cancer J. Clin. 60, 277-300 (2010).
2. Hodi FS, O'Day SJ, McDermott DF et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010). nn First study to show a survival advantage of any treatment for melanoma.
3. Bhatia S, Tykodi S, Thompson J: Treatment of malignant melanoma: an overview. Oncology (Williston Park) 23(6), 488-496 (2009).
4. Bergen, Chen R, Gonzalez R: Efficacy and safety of HLA-B7/β2- microglobulin plasmid DNA/lipid complex (Allovectin-7®) in patients with metastatic melanoma. Exp. Opin. Biol. Ther. 3(2), 377-384 (2003). (Pubitemid 36458767)
5. Goff SL, Smith FO, Klapper JA et al.: Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J. Immunother. 33(8), 840-847 (2010).
6. Flaherty KT, Schiller J, Schuchter LM et al.: A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14, 4836-4842 (2008). nn Phase I study evaluating antitumor activity and safety of dosing a multikinase inhibitory agent in conjunction with chemotherapy in patients with solid tumors.
7. Hodi FS, Friedlander P, Corless CL et al.: Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046-2051 (2008). nn Case study of responses to imatinib, which inhibits the KIT-activating mutation found in metastatic melanoma.
8. Thompson D, Flaherty K, Messersmith W et al.: A three-part, Phase I dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally with solid tumors or lymphoma. J. Clin. Oncol. 27(Suppl.), E14584 (2009).
9. Atkins MB, Hsu J, Lee S et al.: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon a-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 26(35), 5748-5754 (2008). n Randomized trial of biochemotherapy versus chemotherapy, showing no advantage of biochemotherapy.
10. Hicklin DG, Wang Z, Arienti F et al.: β2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest. 101(12), 2720-2729 (1998). (Pubitemid 28294581)
11. Halama N, Zoernig I, Jaeger D: Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J. Oncol. DOI:10.1155/2010/689893 (2010) (Epub ahead of print).
12. Lewis KD, Humes TN, Gonzalez R: Current status and future prospects of gene therapy: focus on Allovectin-7® in the treatment of melanoma. Am. J. Cancer 4(3), 137-144 (2005). nn Phase II trial evaluating the response rate, time to progression and survival of patients with direct intratumoral injection of Allovectin-7®. (Pubitemid 41126922)
13. Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE: IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J. Immunol. 12, 6378-6385 (1999).
14. Kudchadkar R, Gonzalez R: Velimogene aliplasmid lipid complex. Drugs of the Future 32(10), 874-878 (2007).
15. Lew D, Parker SE, Latimer T et al.: Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum. Gene Ther. 6(5), 553-564 (1995).
16. Nabel GJ, Nabel EG, Yang ZY et al.: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl Acad. Sci. USA 90, 11307-11311 (1993).
17. Nabel GJ, Nabel EG, Yang ZY et al.: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl Acad. Sci. USA 93, 15388-15393 (1996). nn First study to demonstrate the safety and therapeutic benefit of direct gene transfer of the recombinant HLA-B7 protein via plasmid injection in HLA-B7-negative patients with advanced melanoma.
18. Stopeck AT, Hersh EM, Akporiaye ET et al.: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J. Clin. Oncol. 15, 341-349 (1997). nn Clinical trial that showed DNA-liposome complexes encoding an allogeneic MHC protein stimulated local antitumor immune responses that facilitated the generation of effector cells for the immunotherapy of cancer. (Pubitemid 27020592)
19. Stopeck AT, Jones A, Hersh EM et al.: Phase II study of direct intralesional gene transfer of Allovectin-7®, a HLA-B7/β2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin. Cancer Res. 7, 2285-2291 (2001). (Pubitemid 32751626)
20. Gonzalez R, Hutchins L, Nemunaitis J et al.: Phase II trial of Allovectin-7® in advanced metastatic melanoma. Melanoma Res. 16, 521-526 (2006). n Phase II study that showed the safety and biologic activity of Allovectin-7 at the dose of 10 μg intralesionally. (Pubitemid 44934710)
21. Bedikian AY, Richards J, Kharkevitch D et al.: A Phase II study of high-dose Allovectin-7® in patients with advanced metastatic melanoma. Melanoma Res. 20(3), 218-226 (2010). n Phase II study that showed the safety of intralesional Allovectin-7 at a high dose.